{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"SIGA","limit":50},"count":50,"signals":[{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":55,"context":"ilure to secure in a timely mannerand perform additional U.S. Government contracts after the 19C BARDA Contract to substantially maintain or expand the U.S. Government stockpile of TPOXX could have a material adverse effect on our long-term business, financial condition, results of operations, including losses due to potential inventory write-offs,and prospects. Additionally, the 19C BARDA Contract does not necessarily","filed_date":"2026-03-10","accession":"0001437749-26-007557","full_text":"https://origin.rootz.global/static/filing/0001437749-26-007557.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"compensation, including stock-based awards, of similarly situated executives at peer companies. In May2023, Mr.Luckshire and Dr.Hruby received the following RSU awards that vest in equal yearly installments over a period of two years with half of the RSUs vesting on July1, 2024 and the other half vesting on July1, 2025, subject to continued employment through the applicable vesting date: | | | | |","filed_date":"2025-04-28","accession":"0001140361-25-016016","full_text":"https://origin.rootz.global/static/filing/0001140361-25-016016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"ent | | | 13 | | | Ownership of Common Stock | | | 13 | | | Management | | | 15 | | | Executive Officers | | | 15 | | | Compensation Discussion and Analysis | | | 16 | | | Overview | | | 16 | | | Our Named Executive Officers | | | 16 | | | Our Compensation Philosophy & Program Objectives | | | 16 | | | Our Executive Compensation Decision Process | | | 17 | | | Our Executive Compensation Program in Detail | | | 19 | | |","filed_date":"2025-04-28","accession":"0001140361-25-016016","full_text":"https://origin.rootz.global/static/filing/0001140361-25-016016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":51,"context":"kpile of TPOXX. Failure to secure and perform additional U.S. Government contracts after the 19C BARDA Contract to substantially maintain or expand the U.S. Government stockpile of TPOXX could have a material adverse effect on our long-term business, financial condition, results of operations and prospects. Additionally, the 19C BARDA Contract does not necessarily increase the likelihood that we will secure future compa","filed_date":"2025-03-11","accession":"0001437749-25-007056","full_text":"https://origin.rootz.global/static/filing/0001437749-25-007056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"ent | | | 13 | | | Ownership of Common Stock | | | 13 | | | Management | | | 15 | | | Executive Officers | | | 15 | | | Compensation Discussion and Analysis | | | 16 | | | Overview | | | 16 | | | Our Named Executive Officers | | | 16 | | | Our Compensation Philosophy & Program Objectives | | | 16 | | | Our Executive Compensation Decision Process | | | 17 | | | Our Executive Compensation Program in Detail | | | 19 | | |","filed_date":"2024-04-26","accession":"0001140361-24-022264","full_text":"https://origin.rootz.global/static/filing/0001140361-24-022264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":51,"context":"kpile of TPOXX. Failure to secure and perform additional U.S. Government contracts after the 19C BARDA Contract to substantially maintain or expand the U.S. Government stockpile of TPOXX could have a material adverse effect on our long-term business, financial condition, results of operations and prospects. Additionally, the 19C BARDA Contract does not necessarily increase the likelihood that we will secure future compa","filed_date":"2024-03-12","accession":"0001437749-24-007487","full_text":"https://origin.rootz.global/static/filing/0001437749-24-007487.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":31,"context":"hip of Common Stock | | | 14 | | | Management | | | 16 | | | Executive Officers | | | 16 | | | Compensation Discussion and Analysis | | | 17 | | | Overview | | | 17 | | | Our Named Executive Officers | | | 17 | | | Our Executive Compensation Decision Process | | | 17 | | | Our Executive Compensation Program | | | 19 | | | Our Compensation Policies | | | 22 | | | Compensation","filed_date":"2023-04-26","accession":"0001140361-23-020420","full_text":"https://origin.rootz.global/static/filing/0001140361-23-020420.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"r expanding its stockpile of TPOXX®. Failure to secure and perform additional contracts after the 19C BARDA Contract to substantially maintain or expand the stockpile of TPOXX® could have a material adverse effect on our long-term business, financial condition, results of operations and prospects. Additionally, the 19C BARDA Contract does not necessarily increase the likelihood that we will secure future compa","filed_date":"2023-03-02","accession":"0001437749-23-005241","full_text":"https://origin.rootz.global/static/filing/0001437749-23-005241.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"ent | | | 14 | | | Ownership of Common Stock | | | 14 | | | Management | | | 16 | | | Executive Officers | | | 16 | | | Compensation Discussion and Analysis | | | 17 | | | Overview | | | 17 | | | Our Named Executive Officers | | | 17 | | | Our Executive Compensation Decision Process | | | 17 | | | Our Executive Compensation Program | | | 19 | | | Our Compensation Policies | | | 22 | | | Compensation Committee Report | |","filed_date":"2022-04-27","accession":"0001140361-22-016274","full_text":"https://origin.rootz.global/static/filing/0001140361-22-016274.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"r expanding its stockpile of TPOXX®. Failure to secure and perform additional contracts after the 19C BARDA Contract to substantially maintain or expand the stockpile of TPOXX® could have a material adverse effect on our long-term business, financial condition, results of operations and prospects. Additionally, the 19C BARDA Contract does not necessarily increase the likelihood that we will secure future compa","filed_date":"2022-03-03","accession":"0001437749-22-005179","full_text":"https://origin.rootz.global/static/filing/0001437749-22-005179.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"ovide guidance in government relations, particularly with the Department of Defense and other government agencies. Phillip L. Gomez began serving as Chief Executive Officer on October13, 2016 and was appointed as a director on December6, 2016. Prior to joining SIGA, Dr. Gomez was a Principal in the Pharma & Life Sciences Management Consulting Practice at PricewaterhouseCoopers LLP (PwC) from 2011 until 2016. At PwC, and","filed_date":"2021-04-27","accession":"0001140361-21-014598","full_text":"https://origin.rootz.global/static/filing/0001140361-21-014598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"r expanding its stockpile of TPOXX®. Failure to secure and perform additional contracts after the 19C BARDA Contract to substantially maintain or expand the stockpile of TPOXX® could have a material adverse effect on our long-term business, financial condition, results of operations and prospects. Additionally, the 19C BARDA Contract does not necessarily increase the likelihood that we will secure future compa","filed_date":"2021-03-04","accession":"0001437749-21-005031","full_text":"https://origin.rootz.global/static/filing/0001437749-21-005031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"rovide guidance in government relations, particularly with the Department of Defense and other government agencies. Phillip L Gomez began serving as Chief Executive Officer on October13, 2016 and was appointed as a director on December6, 2016. Prior to joining SIGA, Dr. Gomez was a Principal in the Pharma & Life Sciences Management Consulting Practice at PricewaterhouseCoopers LLP (PwC) since 2011. At PwC, and at PRTM M","filed_date":"2020-04-28","accession":"0001140361-20-009995","full_text":"https://origin.rootz.global/static/filing/0001140361-20-009995.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"aintaining or expanding its stockpile of TPOXX. Failure to secure and perform additional contracts after the 19C BARDA Contract to substantially maintain or expand the stockpile of TPOXX could have a material adverse effect on our long-term business, financial condition and operating results. Additionally, the 19C BARDA Contract does not necessarily increase the likelihood that we will secure future comparable contracts","filed_date":"2020-03-05","accession":"0001010086-20-000006","full_text":"https://origin.rootz.global/static/filing/0001010086-20-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":18,"context":"Directors many years of experience counseling public companies with respect to governance and other legal matters. Phillip L Gomez began serving as Chief Executive Officer on October 13, 2016 and was appointed as a director on December 6, 2016. Prior to joining SIGA, Dr. Gomez was a Principal in the Pharma & Life Sciences Management Consulting Practice at PricewaterhouseCoopers LLP (PwC) since 2011. At PwC, and at PRTM","filed_date":"2019-04-29","accession":"0001140361-19-007876","full_text":"https://origin.rootz.global/static/filing/0001140361-19-007876.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"mmitment to maintaining or expanding its stockpile of TPOXX. Failure to secure and perform additional contracts after the 2018 BARDA Contract to maintain or expand the stockpile of TPOXX could have a material adverse effect on our long-term business, financial condition and operating results. Additionally, the 2018 BARDA Contract does not necessarily increase the likelihood that we will secure future comparable contract","filed_date":"2019-03-06","accession":"0001010086-19-000007","full_text":"https://origin.rootz.global/static/filing/0001010086-19-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":22,"context":"el J. Bayer, Thomas E. Constance, Phillip L. Gomez, Jeffrey B. Kindler, Joseph W. Marshall III, Eric A. Rose, Michael C. Plansky and Paul G. Savas. Director Nominee Information Eric A. Rose, M.D. was appointed Executive Chairman of the Board of Directors on October 13, 2016. Prior to such date, he had served as Chairman of the Board of Directors since January 25, 2007, and as the Companys Chief Executive Officer since March","filed_date":"2018-04-18","accession":"0001140361-18-018901","full_text":"https://origin.rootz.global/static/filing/0001140361-18-018901.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"m the BARDA Contract in the time periods we anticipate or at all, or that we will be able to secure future contracts. Failure to recognize such revenue or secure such contracts or grants could have a material adverse effect on our results of operations. Government procurement contracts are mostly set at fixed prices and such pricing is based on estimates of the time, resources and expenses required to perform these cont","filed_date":"2018-03-06","accession":"0001010086-18-000003","full_text":"https://origin.rootz.global/static/filing/0001010086-18-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"nt. (a) From the Commencement Date through the sixty third (63rd) month of the term of the lease, the sum of Three Hundred Four Thousand ($304,000.00) Dollars per annum, payable in equal monthly installments of Twenty Five Thousand Three Hundred Thirty Three and 33/100 ($25,333.33) Dollars. (b) From the first day of the sixty fourth month of the term of the lease through the expiration or earlier ter","filed_date":"2017-05-30","accession":"0001140361-17-022812","full_text":"https://origin.rootz.global/static/filing/0001140361-17-022812.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"ckholders. The Board and management thank these departing board members. Michael C. Plansky has been nominated to become a director of the Company. Director Nominee Information Eric A. Rose, M.D. was appointed Executive Chairman of the Board of Directors on October 13, 2016. Prior to such date, he had served as Chairman of the Board of Directors since January 25, 2007, and as the Companys Chief Executive Officer since March","filed_date":"2017-04-17","accession":"0001626129-17-000256","full_text":"https://origin.rootz.global/static/filing/0001626129-17-000256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"A Contract in the time periods we anticipate or at all, or that we will be able to secure future contracts or grants. Failure to recognize such revenue or secure such contracts or grants could have a material adverse effect on our results of operations. The pricing under our fixed-price government contracts and grants is based on estimates of the time, resources and expenses required to perform these contracts and grant","filed_date":"2017-03-07","accession":"0001010086-17-000005","full_text":"https://origin.rootz.global/static/filing/0001010086-17-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"urisdiction of such Loan Partys organization and a certificate of foreign qualification from each jurisdiction where such Loan Partys failure to be so qualified could reasonably be expected to have a Material Adverse Effect, in each case certified as of a recent date reasonably acceptable to Agent; (c) certified copies, dated as of a recent date reasonably acceptable to the Requisite Lenders, of UCC, judgment, bankruptc","filed_date":"2016-09-07","accession":"0001140361-16-079092","full_text":"https://origin.rootz.global/static/filing/0001140361-16-079092.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"The Plan requires that we comply with certain restrictive covenants regarding our operations until the PharmAthene Judgment is satisfied under the Plan. Compliance with these requirements may have a material adverse effect on our ability to operate our business. ***If we default on the restrictive covenants contained in the Plan, the composition of the Board of Directors will be******significantly altered and the Compa","filed_date":"2016-06-06","accession":"0001567619-16-002468","full_text":"https://origin.rootz.global/static/filing/0001567619-16-002468.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":22,"context":"curities as of May 24, 2016 of (i) each person known to SIGA to own beneficially more than 5% of the applicable class of voting securities, (ii) each director and director nominee of SIGA, (iii) each Named Executive Officer and (iv) all directors and executive officers of SIGA as a group. As of May 24, 2016, a total of 54,284,296 shares of common stock were outstanding. Each share of common stock is entitled to one vote","filed_date":"2016-06-06","accession":"0001567619-16-002468","full_text":"https://origin.rootz.global/static/filing/0001567619-16-002468.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"rities as of March 15, 2016 of (i) each person known to SIGA to own beneficially more than 5% of the applicable class of voting securities, (ii) each director and director nominee of SIGA, (iii) each Named Executive Officer and (iv) all directors and executive officers of SIGA as a group. As of March 15, 2016, a total of 54,114,296 shares of Common Stock were outstanding. Each share of Common Stock is entitled to one vo","filed_date":"2016-04-18","accession":"0001626129-16-000570","full_text":"https://origin.rootz.global/static/filing/0001626129-16-000570.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"e of the PharmAthene Allowed Claim. Option 1 shall only be available if the PharmAthene Final Order provides for a single lump sum payment (but not periodic royalty payments or other periodic or installment payments), together with any interest, fees and expenses included in such PharmAthene Final Order, to be paid to PharmAthene (such payment award pursuant to the PharmAthene Final Order, a Lump Sum","filed_date":"2016-04-14","accession":"0001140361-16-061132","full_text":"https://origin.rootz.global/static/filing/0001140361-16-061132.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"xvii), (xxviii), (xxix), (xxx), (xxxi), (xxxii) or (xxxiii); or (2) any other Plan Covenant that by its terms is expressly modified by a materiality qualifier or otherwise tied to the occurrence of a Material Adverse Effect (as such term is defined in the Plan Covenants); or (3) any other Plan Covenant not otherwise included in clauses (1) or (2) above that specifies a dollar or percentage cap; provided, however, that n","filed_date":"2016-04-14","accession":"0001140361-16-061132","full_text":"https://origin.rootz.global/static/filing/0001140361-16-061132.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":18,"context":"for purposes of this Agreement providing for the payment of any amounts or benefits subject to Section 409A of the Code upon or following a termination of employment unless such termination is also a separation from service within the meaning of Section 409A of the Code and, for purposes of any such provision of this Agreement, references to a termination, termination of employment or like terms shall mean separ","filed_date":"2016-04-14","accession":"0001140361-16-061132","full_text":"https://origin.rootz.global/static/filing/0001140361-16-061132.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":7,"context":"th certain restrictive covenants regarding our operations until the PharmAthene claim (as described below) is satisfied under the Plan of Reorganization. Compliance with these requirements may have a material adverse effect on our ability to operate our business. If we default on the restrictive covenants contained in our Plan of Reorganization, the composition of the Board of Directors would be significantly altered an","filed_date":"2016-03-04","accession":"0001010086-16-000019","full_text":"https://origin.rootz.global/static/filing/0001010086-16-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"e of the PharmAthene Allowed Claim. Option 1 shall only be available if the PharmAthene Final Order provides for a single lump sum payment (but not periodic royalty payments or other periodic or installment payments), together with any interest, fees and expenses included in such PharmAthene Final Order, to be paid to PharmAthene (such payment award pursuant to the PharmAthene Final Order, a Lump Sum","filed_date":"2015-12-16","accession":"0001140361-15-044769","full_text":"https://origin.rootz.global/static/filing/0001140361-15-044769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"xvii), (xxviii), (xxix), (xxx), (xxxi), (xxxii) or (xxxiii); or (2) any other Plan Covenant that by its terms is expressly modified by a materiality qualifier or otherwise tied to the occurrence of a Material Adverse Effect (as such term is defined in the Plan Covenants); or (3) any other Plan Covenant not otherwise included in clauses (1) or (2) above that specifies a dollar or percentage cap; provided, however, that n","filed_date":"2015-12-16","accession":"0001140361-15-044769","full_text":"https://origin.rootz.global/static/filing/0001140361-15-044769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"for purposes of this Agreement providing for the payment of any amounts or benefits subject to Section 409A of the Code upon or following a termination of employment unless such termination is also a separation from service within the meaning of Section 409A of the Code and, for purposes of any such provision of this Agreement, references to a termination, termination of employment or like terms shall mean separ","filed_date":"2015-12-16","accession":"0001140361-15-044769","full_text":"https://origin.rootz.global/static/filing/0001140361-15-044769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"rities as of March 23, 2015 of (i) each person known to SIGA to own beneficially more than 5% of the applicable class of voting securities, (ii) each director and director nominee of SIGA, (iii) each Named Executive Officer and (iv) all directors and executive officers of SIGA as a group. As of March 23, 2015, a total of 53,504,296 shares of Common Stock were outstanding. Each share of Common Stock is entitled to one vo","filed_date":"2015-04-14","accession":"0001206774-15-001258","full_text":"https://origin.rootz.global/static/filing/0001206774-15-001258.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"their proprietary rights that we are not aware of, or third parties may succeed in marketing equivalent or superior drug products. Our failure to develop safe, commercially viable drugs would have a material adverse effect on our business, financial condition and results of operations. Risks Related to Commercialization Our ability to grow our business depends significantly on our ability to achieve sales of Tecovirim","filed_date":"2015-03-06","accession":"0001010086-15-000004","full_text":"https://origin.rootz.global/static/filing/0001010086-15-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":30,"context":"rities as of March 14, 2014 of (i) each person known to SIGA to own beneficially more than 5% of the applicable class of voting securities, (ii) each director and director nominee of SIGA, (iii) each Named Executive Officer and (iv) all directors and executive officers of SIGA as a group. As of March 14, 2014, a total of 53,327,909 shares of Common Stock were outstanding. Each share of Common Stock is entitled to one vo","filed_date":"2014-04-15","accession":"0001206774-14-001237","full_text":"https://origin.rootz.global/static/filing/0001206774-14-001237.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":28,"context":"ckholders and until their successors have been duly elected and qualified. Unless otherwise instructed, the proxy holders will vote the proxies received by them FOR the election of the twelve persons named in the table below as directors of SIGA. Proxies cannot be voted for a greater number of persons than the nominees named. In the event that any of the below listed nominees for director should become unavailable for election for a","filed_date":"2013-04-16","accession":"0001206774-13-001471","full_text":"https://origin.rootz.global/static/filing/0001206774-13-001471.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":6,"context":"their proprietary rights that we are not aware of, or third parties may succeed in marketing equivalent or superior drug products. Our failure to develop safe, commercially viable drugs would have a material adverse effect on our business, financial condition and results of operations. Risks Related to Commercialization Our ability to grow our business depends significantly on our ability to achieve sales of Arestvyr","filed_date":"2013-03-06","accession":"0001010086-13-000004","full_text":"https://origin.rootz.global/static/filing/0001010086-13-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"urisdiction of such Loan Partys organization and a certificate of foreign qualification from each jurisdiction where such Loan Partys failure to be so qualified could reasonably be expected to have a Material Adverse Effect, in each case certified as of a recent date reasonably acceptable to Agent; (g) an Access Agreement for each leased location or third party location to the extent required pursuant to Section 6.6;","filed_date":"2013-01-07","accession":"0001206774-13-000093","full_text":"https://origin.rootz.global/static/filing/0001206774-13-000093.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":19,"context":"ckholders and until their successors have been duly elected and qualified. Unless otherwise instructed, the proxy holders will vote the proxies received by them FOR the election of the eleven persons named in the table below as directors of SIGA. Proxies cannot be voted for a greater number of persons than the nominees named. In the event that any of the below listed nominees for director should become unavailable for election for a","filed_date":"2012-04-27","accession":"0001206774-12-001732","full_text":"https://origin.rootz.global/static/filing/0001206774-12-001732.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":6,"context":"their proprietary rights that we are not aware of, or third parties may succeed in marketing equivalent or superior drug products. Our failure to develop safe, commercially viable drugs would have a material adverse effect on our business, financial condition and results of operations. Risks Related to Commercialization Our ability to grow our business depends significantly on our ability to achieve sales of ST-246 to","filed_date":"2012-03-01","accession":"0001010086-12-000005","full_text":"https://origin.rootz.global/static/filing/0001010086-12-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"ckholders and until their successors have been duly elected and qualified. Unless otherwise instructed, the proxy holders will vote the proxies received by them FOR the election of the eleven persons named in the table below as directors of SIGA. Proxies cannot be voted for a greater number of persons than the nominees named. In the event that any of the below listed nominees for director should become unavailable for election for a","filed_date":"2011-04-12","accession":"0001206774-11-000814","full_text":"https://origin.rootz.global/static/filing/0001206774-11-000814.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"Stockholders and until their successors have been duly elected and qualified. Unless otherwise instructed, the proxy holders will vote the proxies received by them FOR the election of the ten persons named in the table below as directors of SIGA. Proxies cannot be voted for a greater number of persons than the nominees named. In the event that any of the below listed nominees for director should become unavailable for election for a","filed_date":"2010-04-12","accession":"0001206774-10-000926","full_text":"https://origin.rootz.global/static/filing/0001206774-10-000926.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":18,"context":"ckholders and until their successors have been duly elected and qualified. Unless otherwise instructed, the proxy holders will vote the proxies received by them FOR the election of the twelve persons named in the table below as directors of SIGA. Proxies cannot be voted for a greater number of persons than the nominees named. In the event that any of the below listed nominees for director should become unavailable for election for a","filed_date":"2009-04-08","accession":"0001169232-09-002021","full_text":"https://origin.rootz.global/static/filing/0001169232-09-002021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"Stockholders and until their successors have been duly elected and qualified. Unless otherwise instructed, the proxy holders will vote the proxies received by them FOR the election of the ten persons named in the table below as directors of SIGA. Proxies cannot be voted for a greater number of persons than the nominees named. In the event that any of the below listed nominees for director should become unavailable for election for a","filed_date":"2008-04-09","accession":"0001169232-08-001619","full_text":"https://origin.rootz.global/static/filing/0001169232-08-001619.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":44,"context":"o) shall not be deemed to be an admission or acknowledgment, in and of itself, that such information is required by the terms hereof to be disclosed, is material, has resulted in or would result in a Material Adverse Effect (as defined below), or is outside the ordinary course of business. For purposes of this Agreement, the phrase **to the knowledge of****Pharmathene** or any phrase of similar import shall mean the act","filed_date":"2006-06-13","accession":"0000922423-06-000877","full_text":"https://origin.rootz.global/static/filing/0000922423-06-000877.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement, any Capital Lease having substantially the same economic effect as any of the foregoing. Material Adverse Effect: a material adverse effect on (i) the business, operations, property or, condition (financial or otherwise) or prospects of the Issuer, (ii) the ability of the Issuer to perform its obligations under","filed_date":"2006-03-22","accession":"0000922423-06-000404","full_text":"https://origin.rootz.global/static/filing/0000922423-06-000404.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":93,"match_count":6,"context":"their proprietary rights that we are not aware of, or third parties may succeed in marketing equivalent or superior drug products. Our failure to develop safe, commercially viable drugs would have a material adverse effect on our business, financial condition and results of operations. Risks Related to Commercialization Our ability to grow our business depends significantly on our ability to achieve sales of Arestvyr","filed_date":"2014-03-10","accession":"0001010086-14-000006","full_text":"https://origin.rootz.global/static/filing/0001010086-14-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":85,"match_count":5,"context":"their proprietary rights that we are not aware of, or third parties may succeed in marketing equivalent or superior drug products. Our failure to develop safe, commercially viable drugs would have a material adverse effect on our business, financial condition and results of operations. Risks Related to Commercialization Because we must obtain regulatory clearance or otherwise operate under strict legal requirements in","filed_date":"2010-03-10","accession":"0001206774-10-000542","full_text":"https://origin.rootz.global/static/filing/0001206774-10-000542.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"xa0; In connection with a potential FDA label expansion of oral TPOXX® for an indication covering smallpox post-exposure prophylaxis (“PEP”), the Company has recently completed enrollment of an immunogenicity trial and is planning to meet target enrollment for an expanded safety trial in March of 2023.  Provided unblinded results from these trials are supportive of a","filed_date":"2023-03-02","accession":"0001437749-23-005241","full_text":"https://origin.rootz.global/static/filing/0001437749-23-005241.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SIGA","company":"SIGA TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":77,"match_count":4,"context":"their proprietary rights that we are not aware of, or third parties may succeed in marketing equivalent or superior drug products. Our failure to develop safe, commercially viable drugs would have a material adverse effect on our business, financial condition and results of operations. Risks Related to Commercialization Because we must obtain regulatory clearance or otherwise operate under strict legal requirements i","filed_date":"2011-03-09","accession":"0001206774-11-000458","full_text":"https://origin.rootz.global/static/filing/0001206774-11-000458.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"89c00b8183eb66e25d7acdc4fd333b6473bcced615b0fb040f24653041dc6916","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"c3dd0bb8115f56ad460be1ac99506824f79f037a0fd90774a05a55b5bb00295f","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":33,"hourly_limit":500,"remaining":467,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}